Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines.

Tempero MA, Malafa MP, Behrman SW, Benson AB 3rd, Casper ES, Chiorean EG, Chung V, Cohen SJ, Czito B, Engebretson A, Feng M, Hawkins WG, Herman J, Hoffman JP, Ko A, Komanduri S, Koong A, Lowy AM, Ma WW, Merchant NB, Mulvihill SJ, Muscarella P 2nd, Nakakura EK, Obando J, Pitman MB, Reddy S, Sasson AR, Thayer SP, Weekes CD, Wolff RA, Wolpin BM, Burns JL, Freedman-Cass DA.

J Natl Compr Canc Netw. 2014 Aug;12(8):1083-93.

PMID:
25099441
2.

Novel directions in neoadjuvant therapy for pancreas adenocarcinoma.

Yang A, O'Reilly EM.

Expert Rev Gastroenterol Hepatol. 2015 May;9(5):585-601. doi: 10.1586/17474124.2015.1012496. Epub 2015 Feb 16. Review.

PMID:
25686370
3.

Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines.

Tempero MA, Arnoletti JP, Behrman SW, Ben-Josef E, Benson AB 3rd, Casper ES, Cohen SJ, Czito B, Ellenhorn JD, Hawkins WG, Herman J, Hoffman JP, Ko A, Komanduri S, Koong A, Ma WW, Malafa MP, Merchant NB, Mulvihill SJ, Muscarella P 2nd, Nakakura EK, Obando J, Pitman MB, Sasson AR, Tally A, Thayer SP, Whiting S, Wolff RA, Wolpin BM, Freedman-Cass DA, Shead DA; National Comprehensive Cancer Networks.

J Natl Compr Canc Netw. 2012 Jun 1;10(6):703-13.

4.

Therapy of locally advanced pancreatic adenocarcinoma: unresectable and borderline patients.

Kircher SM, Krantz SB, Nimeiri HS, Mulcahy MF, Munshi HG, Benson AB 3rd.

Expert Rev Anticancer Ther. 2011 Oct;11(10):1555-65. doi: 10.1586/era.11.125. Review.

PMID:
21999129
5.

Contemporary Management of Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer.

Shaib WL, Ip A, Cardona K, Alese OB, Maithel SK, Kooby D, Landry J, El-Rayes BF.

Oncologist. 2016 Feb;21(2):178-87. doi: 10.1634/theoncologist.2015-0316. Epub 2016 Feb 1. Review.

6.

Neoadjuvant chemoradiation to convert locally advanced pancreatic body adenocarcinoma to resectable disease.

Cunningham SC, Cusnir M, Burdick RK, Van Echo DA, Moesinger R.

Clin Adv Hematol Oncol. 2003 Dec;1(12):741-2; discussion 743. No abstract available.

PMID:
16258479
7.

Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy.

Addeo P, Rosso E, Fuchshuber P, Oussoultzoglou E, De Blasi V, Simone G, Belletier C, Dufour P, Bachellier P.

Oncology. 2015;89(1):37-46. doi: 10.1159/000371745. Epub 2015 Mar 7.

PMID:
25766660
8.

Treatment of borderline resectable pancreatic cancer.

Cooper AB, Tzeng CW, Katz MH.

Curr Treat Options Oncol. 2013 Sep;14(3):293-310. doi: 10.1007/s11864-013-0244-6.

PMID:
23793524
9.

Pancreatic Cancer in the Era of Neoadjuvant Therapy: A Narrative Overview.

Casciani F, Marchegiani G, Malleo G, Bassi C, Salvia R.

Chirurgia (Bucur). 2018 May-Jun;113(3):307-317. doi: 10.21614/chirurgia.113.3.307. Review.

10.

Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival.

Rose JB, Rocha FG, Alseidi A, Biehl T, Moonka R, Ryan JA, Lin B, Picozzi V, Helton S.

Ann Surg Oncol. 2014 May;21(5):1530-7. doi: 10.1245/s10434-014-3486-z. Epub 2014 Jan 29. Erratum in: Ann Surg Oncol. 2014 May;21(5):1538. Dosage error in article text.

PMID:
24473642
11.
12.

Preoperative chemoradiation for patients with locally advanced adenocarcinoma of the pancreas.

White R, Lee C, Anscher M, Gottfried M, Wolff R, Keogan M, Pappas T, Hurwitz H, Tyler D.

Ann Surg Oncol. 1999 Jan-Feb;6(1):38-45.

PMID:
10030414
13.

Preoperative chemoradiation therapy for pancreatic cancer.

Evans DB, Pisters PW.

Surg Clin North Am. 2001 Jun;81(3):709-13.

PMID:
11459284
14.

Management of a patient with borderline resectable pancreatic cancer. Case report and review.

Shah AP, Strauss JB, Leslie WT, Shah A, Mahon B, Abrams RA.

Oncology (Williston Park). 2008 Nov 30;22(13):1524-9. Review.

15.

Neoadjuvant chemotherapy in resectable pancreatic cancer.

Irmscher S, Senninger N, Schleicher C.

Ann Surg Oncol. 2008 Jul;15(7):2059-60; author reply 2061. doi: 10.1245/s10434-007-9796-7. Epub 2008 Feb 12. No abstract available.

PMID:
18266042
16.

Perioperative Therapy for Surgically Resectable Pancreatic Adenocarcinoma.

Du L, DeFoe M, Ruzinova MB, Olsen JR, Wang-Gillam A.

Hematol Oncol Clin North Am. 2015 Aug;29(4):717-26. doi: 10.1016/j.hoc.2015.04.011. Epub 2015 May 30. Review.

17.

[Chemoradiation for pancreatic adenocarcinoma].

Flandin I, Mornex F, Claude L, Kubas A, Khodri M, Wautot V, Mazeron R, Partensky C.

Cancer Radiother. 2004 Nov;8 Suppl 1:S80-7. Review. French.

PMID:
15679252
18.

Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and locally-advanced pancreatic cancer.

Rajagopalan MS, Heron DE, Wegner RE, Zeh HJ, Bahary N, Krasinskas AM, Lembersky B, Brand R, Moser AJ, Quinn AE, Burton SA.

Radiat Oncol. 2013 Oct 31;8:254. doi: 10.1186/1748-717X-8-254.

19.

Diagnosis and Management of Borderline Resectable Pancreatic Adenocarcinoma.

Schwarz L, Katz MH.

Hematol Oncol Clin North Am. 2015 Aug;29(4):727-40. doi: 10.1016/j.hoc.2015.04.004. Epub 2015 Jun 9. Review.

PMID:
26226907
20.

Serum CA 19-9 response to neoadjuvant therapy is associated with outcome in pancreatic adenocarcinoma.

Boone BA, Steve J, Zenati MS, Hogg ME, Singhi AD, Bartlett DL, Zureikat AH, Bahary N, Zeh HJ 3rd.

Ann Surg Oncol. 2014 Dec;21(13):4351-8. doi: 10.1245/s10434-014-3842-z. Epub 2014 Aug 5.

PMID:
25092157

Supplemental Content

Support Center